Why the study?
Extracellular vesicles from hypoxia-preconditioned mesenchymal stem cells show early cardioprotective effects against myocardial infarction compared to normoxic mesenchymal stem cell-derived vesicles, but their cardioprotective mechanisms are not fully understood.
Do extracellular vesicles from hypoxia-preconditioned mesenchymal stem cells reduce myocardial injury in a mouse model of myocardial infarction?
Do extracellular vesicles from hypoxia-preconditioned mesenchymal stem cells reduce myocardial injury in a mouse model of myocardial infarction?
Extracellular vesicles from hypoxia-preconditioned mesenchymal stem cells alleviate early myocardial infarction injury and apoptosis by transferring miR-224-5p, which targets TXNIP and prevents HIF-1α degradation.
HP-EVs should not yet change clinical MI practice; leaves open human studies of this cardioprotective mechanism.
BACKGROUND: Extracellular vesicles (EVs) derived from hypoxia-preconditioned (HP) mesenchymal stem cells (MSCs) have better cardioprotective effects against myocardial infarction (MI) in the early stage than EVs isolated from normoxic (NC)-MSCs. However, the cardioprotective mechanisms of HP-EVs are not fully understood. AIM: To explore the cardioprotective mechanism of EVs derived from HP MSCs. METHODS: the chromosomal region maintenance-1 (CRM-1)-dependent nuclear transport pathway. RESULTS: . Sequencing of EV-associated miRNAs showed the upregulation of 10 miRNAs predicted to bind TXNIP, an oxidative stress-associated protein. We showed miRNA224-5p, the most upregulated miRNA in HP-EVs, directly combined the 3' untranslated region of TXNIP and demonstrated its critical protective role against hypoxia-mediated CM injury. Our results demonstrated that MI triggered TXNIP-mediated HIF-1α ubiquitination and degradation in the CRM-1-mediated nuclear transport pathway in CMs, which led to aggravated injury and hypoxia tolerance in CMs in the early stage of MI. CONCLUSION: The anti-apoptotic effects of HP-EVs in alleviating MI and the hypoxic conditions of CMs until reperfusion therapy may partly result from EV miR-224-5p targeting TXNIP.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: